Literature DB >> 18316014

[Prevalence of diabetes in france and drug use: study based on the French pharmacovigilance database].

Stéphanie Berthet1, Sabrina Grolleau, Christine Brefel-Courbon, Jean-Louis Montastruc, Maryse Lapeyre-Mestre.   

Abstract

AIM: The aim of this study was to investigate the use of the French Pharmacovigilance Database to estimate characteristics of drug utilization in specific diseases. MATERIALS AND
METHOD: We identified diabetic patients from the French Pharmacovigilance Database between 2002 and 2005. In this population, we studied demographic characteristics, and the patterns of drug use, particularly hypoglycemiant drug use and other drug exposure. In order to validate this approach, we compared our data to a population of patients with diabetes identified from the French Health Insurance System claims database in one French area.
RESULTS: The estimation of prevalence of diabetes was very close in the sources: 2.7% in the French Pharmacovigilance Database and 3.2% in the French Health Insurance System claims database. We found similar results as well for demographic characteristics as for hypoglycemiant drug use and other drug exposure.
CONCLUSION: These results suggest that the French Pharmacovigilance Database may be used to investigate drug utilization patterns.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316014     DOI: 10.2515/therapie:2007076

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  4 in total

1.  Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.

Authors:  Catherine Do; Eric Huyghe; Maryse Lapeyre-Mestre; Jean Louis Montastruc; Haleh Bagheri
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

2.  The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.

Authors:  Francois Montastruc; Agnès Sommet; Emmanuelle Bondon-Guitton; Geneviève Durrieu; Eric Bui; Haleh Bagheri; Maryse Lapeyre-Mestre; Laurent Schmitt; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2011-11-25       Impact factor: 2.953

3.  Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).

Authors:  Neda Tavassoli; Agnes Sommet; Maryse Lapeyre-Mestre; Haleh Bagheri; Jean-Louis Montrastruc
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.

Authors:  Stephanie Berthet; Pascale Olivier; Jean-Louis Montastruc; Maryse Lapeyre-Mestre
Journal:  BMC Clin Pharmacol       Date:  2011-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.